Company Intelligence
Johnson & Johnson is one of the world's largest and most diversified healthcare companies, operating through two major segments: Innovative Medicine (formerly Janssen Pharmaceuticals) and MedTech. Following the 2023 spinoff of its consumer health division as Kenvue (NYSE: KVUE), J&J is now a focused pharmaceutical and medical device company with leading positions in immunology, oncology, neuroscience, cardiovascular, and surgical robotics.
Pharmaceuticals & Life Sciences
Headquarters
New Brunswick, NJ
Employees
~132,000
Revenue
$85.2B (FY2024)
Fiscal Year End
December 31
Founded
1886
Current leadership team based on public filings and announcements.
Joaquin Duato
CEO
Joseph Wolk
CFO
Key events and changes that sales teams should know about.
Completed the full separation of consumer health business Kenvue, enabling J&J to operate as a pure-play pharmaceutical and medical technology company with higher margins, faster growth, and more focused R&D investment.
2025-01
Advanced the Ottava robotic surgery platform, J&J's next-generation robotic-assisted surgical system designed to compete with Intuitive Surgical's da Vinci, with FDA submission expected to reshape the MedTech competitive landscape.
2024-11
Expanded oncology pipeline with multiple late-stage assets and strategic acquisitions, reinforcing Innovative Medicine's position as a top-five global oncology franchise alongside immunology leadership with Tremfya and Stelara successors.
2024-09
Q3 2024 revenue reached $22.5B with Innovative Medicine up 5.5% YoY and MedTech up 5.5%, demonstrating balanced growth across both segments despite Stelara biosimilar competition beginning in Europe.
2024-10
Invested in AI-driven drug discovery partnerships and digital surgery platforms, leveraging machine learning to accelerate clinical development timelines and improve surgical outcomes through real-time AI assistance.
2024-06
The Kenvue spinoff transformed J&J into a higher-growth, higher-margin company focused entirely on pharmaceutical innovation and medical technology. This strategic refocusing means J&J's R&D budget (roughly $15 billion annually) is now concentrated on fewer, higher-impact areas. For vendors selling into pharma and MedTech, understanding this post-separation strategy is essential because J&J's procurement priorities have shifted toward technology that accelerates drug development, enables digital surgery, and supports commercial launch execution.
J&J's Ottava robotic surgery platform represents one of the largest MedTech competitive dynamics to watch. If Ottava gains FDA clearance and commercial traction, it could challenge Intuitive Surgical's dominance in robotic-assisted surgery -- a market expected to exceed $20 billion by 2030. Vendors in the surgical technology, hospital IT, and healthcare services spaces should monitor Ottava's progress closely, as J&J will likely invest heavily in hospital partnerships and infrastructure to support the platform's rollout.
Johnson & Johnson's December 31 fiscal year end aligns with the standard calendar year, but healthcare procurement follows unique cycles. Hospital and health system budgets often operate on different fiscal years, and pharmaceutical procurement is influenced by formulary review cycles, patent expiration timelines, and regulatory approval schedules. Selling into J&J or its customer base requires understanding these healthcare-specific timing dynamics beyond the simple calendar year.
Key competitors based on market analysis and public filings.
Johnson & Johnson's fiscal year ends on December 31, following the standard calendar year. The company reports quarterly results typically in January, April, July, and October, with Q4 and full-year results in late January.
Johnson & Johnson generates approximately $85.2 billion in annual revenue as of FY2024. This revenue comes from two segments: Innovative Medicine (pharmaceuticals) and MedTech (medical devices and surgical solutions). The consumer health business was spun off as Kenvue in 2023.
Johnson & Johnson is headquartered in New Brunswick, New Jersey, where it has been based since its founding in 1886 by Robert Wood Johnson, James Wood Johnson, and Edward Mead Johnson. The company operates in over 60 countries worldwide.
Johnson & Johnson spun off its consumer health division as a separate publicly traded company called Kenvue (NYSE: KVUE) in 2023. Kenvue owns well-known brands like Tylenol, Band-Aid, Neutrogena, and Listerine. The separation allows J&J to focus entirely on its higher-growth pharmaceutical and medical technology businesses.
Johnson & Johnson employs approximately 132,000 people globally following the Kenvue separation. The workforce spans pharmaceutical research, medical device manufacturing, commercial operations, and corporate functions across more than 60 countries.
See leadership changes, strategic initiatives, earnings insights, and buying signals for Johnson & Johnson — updated continuously.
